The Times' article on Juvenon, despite weak caveats, is presented tantalizingly to the general public [“New Life for Aging Cells?,” Aug. 25].
The article's background comments about free radicals and mitochondrial malfunction having a detrimental role in cellular aging are probably correct, but unproven is the implication that that commercial product is therefore clinically beneficial. There is no cited peer-reviewed report, published in a reputable medical journal, of a placebo-controlled long-term study of that pill, in the company-recommended doses, demonstrating its efficacy for "aging" or anything else, in humans.
